

February 4, 2022

VDH COVID-19 Therapeutics Bi-Weekly Update


Total Allocations to Monoclonal Antibody Administration Sites (September 27, 2021 - February 3, 2022):

Monoclonal Antibody	Central	Eastern	Northern	Northwest	Southwest	Total
Bam with Ete	1054	790	353	1450	1923	5570
Ete Solo	370	254	710	500	1311	3145
REGEN – COV	3535	2187	2945	4905	7391	20963
Sotrovimab	1242	1350	2028	1668	1524	7812
Evusheld	2160	912	960	1704	696	6432
Total	8361	5493	6997	10227	12845	43923


Oral Antiviral	Central	Eastern	Northern	Northwest	Southwest	Total
Paxlovid	1120	760	780	1080	1440	5180
Molnupiravir	4100	4000	2640	4220	5220	20180
Total	5220	4760	3420	5300	6660	25360

mAb and Oral Antiviral Distribution Maps

Provider Locations (Monoclonal Antibodies)



Provider Locations (Oral Antivirals)



Reporting Therapeutics Usage & Inventory

- Sites that do not comply with the reporting requirements by 2/22/2022 will NOT receive additional allocations of therapeutics
- Reporting of doses used last week and on-hand to the U.S. Healthcare COVID-19 Portal (i.e., TeleTracking) is required **weekly on Wednesdays by 11:59PM ET** for Bam/Ete, REGEN-COV, and Sotrovimab
 - VDH has published a job aid for reporting into the U.S. Healthcare COVID-19 Portal, which can be accessed [here](#)
- Reporting of doses used and on-hand to HPoP is required **daily by 11:59 PM ET** for Evusheld, Paxlovid, and Molnupiravir
 - VDH is currently developing a job aid for reporting into the Health Partner Order Portal (HPoP)

Bam/Ete and REGEN-COV Monoclonal Antibody Information (HHS Update 1/26/2022)

- The return of Bam/Ete and REGEN-COV is not recommended; any returned product has to be destroyed
- The COVID-19 environment remains dynamic

- Existing monoclonal antibody products (e.g., Bam/Ete, REGEN-COV) may be effective against future variants

Therapeutics Storage (HHS Update 1/26/2022)

- If you have storage concerns or challenges:
 - Consider transferring products to another location/site in your region or health system
 - If your facility does not have the appropriate storage space and you would like to transfer product, please contact covid19therapeutics@vdh.virginia.gov
- If product must be returned:
 - For Bam/Ete, see [The Lilly Return Goods Procedure](#); detailed guidance can be found at: <https://www.lillytrade.com/>
 - For REGEN-COV, call 844-734-6643
 - Note: Reconstituted (diluted) product SHOULD NOT be returned and should be treated as waste per your facility's SOP

Reminder: CMS Code for Outpatient Intravenous Veklury (Remdesivir) Use

- Following a [recent statement from the National Institutes of Health \(NIH\) COVID-19 Treatment Guidelines Panel](#) regarding therapies for COVID-19 Omicron variant, CMS created **HCPCS code J0248** for the antiviral medication Veklury (Remdesivir) when administered in outpatient setting
- [Medicare Administrative Contractors \(MACs\)](#) determine Medicare coverage when no national coverage determination exists, including when providers use FDA-approved drugs for indications other than what is on the approved label
- MACs will determine Medicare coverage for HCPCS code J0248 for Veklury (Remdesivir) administered in the outpatient setting
- See [CMS COVID-19 Provider Toolkit](#) for additional information
- Reimbursement information is still pending with the Virginia MACs
 - The VDH COVID-19 Therapeutics team will update these guidelines as soon as more information is available

Updates to the VDH COVID-19 Treatment Locator Tool

- Please find the locator tool here: [COVID-19 Treatment Locator](#)
- If you are not listed on the Locator Tool and provide appointments to the public, please email covid19therapeutics@vdh.virginia.gov and your information will be added

Upcoming COVID-19 Therapeutics Webinar Details

- Registration links:
 - [Wednesday, 02/09/2022 from 12-1PM](#)
 - [Wednesday, 02/16/2022 from 12-1PM](#)
 - [Wednesday, 02/23/2022 from 12-1PM](#)